Want to see MRMD full AI Analyst Report?
MRMD Stock Chart & Stats
$0.08
>-$0.01(-6.89%)
At close: 4:00 PM EDT
$0.08
>-$0.01(-6.89%)
Day’s Range― - ―
52-Week Range$0.06 - $0.18
Previous CloseN/A
Volume256.86K
Average Volume (3M)516.84K
Market Cap
$32.24M
Enterprise Value$115.28
Total Cash (Recent Filing)$8.44M
Total Debt (Recent Filing)$97.61M
Price to Earnings (P/E)―
Beta0.60
Next Earnings
Nov 11, 2026EPS Estimate
-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding403,040,680
10 Day Avg. Volume744,093
30 Day Avg. Volume516,840
Financial Highlights & Ratios
PEG Ratio-0.15
Price to Book (P/B)0.66
Price to Sales (P/S)0.21
P/FCF Ratio5.25
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.05
Revenue Forecast (FY)$161.00M
Bulls Say, Bears Say
Bulls Say
Broad-based Revenue GrowthRecord revenue and growth across wholesale and retail indicate continued product demand and execution. Growth in 12 of 13 dispensaries and expanding wholesale sales provide a diversified base for scaling over the next several months.
Brand And Distribution StrengthOutgrowing the industry in branded products and expanding storefront availability can deepen shelf presence, improve customer recognition, and support repeat wholesale demand. This strengthens MariMed’s competitive position beyond individual dispensary performance.
Positive Operating Cash FlowPositive operating and free cash flow gives MariMed internal funding capacity for cultivation utilization, retail expansion, and brand investment. Although consistency remains unproven, current liquidity provides more flexibility than a business dependent solely on external capital.
Bears Say
Persistent Losses And Margin CompressionContinued net losses and lower operating margins weaken earnings quality despite revenue growth. If the company cannot convert its expansion and utilization initiatives into durable margin improvement, cash generation and reinvestment capacity could remain constrained.
Elevated Leverage And Reduced FlexibilityHigher leverage increases refinancing and interest-rate sensitivity while limiting flexibility to fund growth or absorb market weakness. Declining equity and negative returns on equity further indicate that the balance sheet remains a structural constraint.
Pricing Pressure And Market SaturationDense dispensary competition and industry-wide wholesale price declines can persistently erode realized pricing, basket size, and store productivity. These pressures are especially relevant in Massachusetts and Illinois, making margin expansion dependent on operational gains.
MariMed News
MRMD FAQ
What was MariMed Inc’s price range in the past 12 months?
MariMed Inc lowest stock price was $0.06 and its highest was $0.18 in the past 12 months.
What is MariMed Inc’s market cap?
MariMed Inc’s market cap is $32.24M.
When is MariMed Inc’s upcoming earnings report date?
MariMed Inc’s upcoming earnings report date is Nov 11, 2026 which is in 66 days.
How were MariMed Inc’s earnings last quarter?
MariMed Inc released its earnings results on Aug 12, 2026. The company reported -$0.007 earnings per share for the quarter, beating the consensus estimate of -$0.01 by $0.003.
Is MariMed Inc overvalued?
According to Wall Street analysts MariMed Inc’s price is currently Overvalued.
Does MariMed Inc pay dividends?
MariMed Inc does not currently pay dividends.
What is MariMed Inc’s EPS estimate?
MariMed Inc’s EPS estimate is -0.01.
How many shares outstanding does MariMed Inc have?
MariMed Inc has 403,040,680 shares outstanding.
What happened to MariMed Inc’s price movement after its last earnings report?
MariMed Inc reported an EPS of -$0.007 in its last earnings report, beating expectations of -$0.01. Following the earnings report the stock price went up 1.563%.
Which hedge fund is a major shareholder of MariMed Inc?
Currently, no hedge funds are holding shares in MRMD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
MariMed Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-52.94%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-3.49%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
MariMed Inc
MariMed Inc. operates in the cannabis industry, specializing in the cultivation, production, and sale of both medicinal and adult-use cannabis items throughout the United States and internationally. The company's diverse product portfolio includes cannabis flowers and concentrates marketed under the Nature's Heritage brand. It also offers infused goods such as chewable tablets and powdered drink mixes under the Kalm Fusion label, natural fruit chews known as Betty's Eddies, and a line of baked treats like brownies and cookies available through Bubby's Baked. Furthermore, MariMed develops cannabidiol (CBD) products under the Florance brand. Beyond its own offerings, the company licenses its various brands and product formulations to others and leases facilities designed for cannabis operations. MariMed Inc., founded in 2011, is based in Norwood, Massachusetts.
MRMD Company Deck
MRMD Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents a generally positive operational and commercial momentum: record quarterly revenue, sequential EBITDA improvement, expanding brand distribution, strong retail transaction growth and rising loyalty membership. These positives are tempered by meaningful year-over-year margin and EBITDA declines driven by industry-wide price compression, elevated promotional activity and localized market saturation (notably Massachusetts). Management characterizes many margin headwinds as transitional and highlights upcoming catalysts (Ohio dispensary, New York entry, improved cultivation utilization, potential regulatory relief) to support future margin expansion.View all MRMD earnings summariesTechnical Analysis
Ownership Overview
10.82% Insiders
0.18% Other Institutional Investors
89.00% Public Companies and
Individual Investors